Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery
PR Newswire•21/10/2026•09:15 ET
0
Key Highlights
- ➤Illumina (ILMN) introduced three BioInsight capabilities in early access.
- ➤DRAGEN Ultra extends analysis beyond variant calling using genomic AI models.
- ➤dnaAI increased disease associations 8% across unsolved cases in large datasets.
- ➤dnaAI ranked established disease-associated variants among top four candidates in 99.4% of genomes.
- ➤Workflow Orchestrator automates traceable sequencing and informatics operations across tens of thousands of samples.
Expert Statements
Rami Mehio, Senior vice president and general manager of BioInsight at Illumina
“The promise of genomics depends on generating vast and complex data, then distilling that data into insights that advance discovery”
Rami Mehio, Senior vice president and general manager of BioInsight at Illumina
“Researchers need consistent, scalable, reproducible workflows, AI that helps identify the samples and findings that matter most, and the ability to study those samples across increasingly large and diverse cohorts.”
Rami Mehio, Senior vice president and general manager of BioInsight at Illumina
“We've put all our new development energy into new capabilities to make it easy to scale insight generation, so research organizations can focus on advancing the science rather than assembling and maintaining software.”
Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery PR Newswire
DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts are now available in early access, incorporating new AI-driven approaches to analysis, automation, and discovery
Get started
Create a free account to read the full story.